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Abstract: Advanced chronic kidney disease (CKD) leads to complications such as anemia, electrolyte abnormalities, bone 
and mineral disorder, and malnutrition-inflammation-atherosclerosis (MIA) syndrome, that result in high cardiovascu-
lar mortality. One of the biomarkers associated with inflammation and cardiovascular events is pregnancy-associated 
plasma protein A (PAPP-A). The aim of the study was to measure serum PAPP-A in hemodialyzed CKD patients, and to 
investigate its correlations with the laboratory markers of the complications. We enrolled 78 consecutive stable adult CKD 
patients treated with maintenance hemodialysis for median period of 60 months. PAPP-A concentrations were measured 
with by electrochemiluminescence immunoassay. Average serum PAPP-A in hemodialyzed patients was almost two times 
higher than the upper reference limit. It positively correlated with N-terminal pro-brain natriuretic peptide (NT-proBNP), 
serum sodium, and the markers of inflammation and malnutrition. In conclusion, serum PAPP-A seems a useful bio-
marker associated with cardiovascular dysfunction, inflammatory state and malnutrition in hemodialysis patients. 
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Introduction
PAPP-A (pregnancy-associated plasma protein A), known also as pappalysin, was first de-
scribed by Lin in 1974 as one of four serum proteins produced by the placenta [1]. Since late 
1990’s, the measurements of serum PAPP-A concentrations together with free βhCG in the 
first trimester of pregnancy have been used in the prenatal screening for fetal chromosomal 
abnormalities (Down syndrome, Edwards syndrome) [2]. Intensive research on PAPP-A has 
lead to the discovery of its structure. Furthermore, the detection of its mRNA in many tissues 
(kidneys, large intestine, endometrium, bones, vascular smooth muscle cells) has stimulated 
the studies on the usefulness of PAPP-A measurements in the course of various diseases not 
associated with pregnancy [2–5]. From the biochemical point of view, PAPP-A is classified 
as a zinc-binding protease belonging to the family of metalloproteinases. It is secreted by 
numerous cells, such as: fibroblasts, vascular smooth muscle cells, osteoblasts, trophoblast 
cells, and, in small amounts, by vascular endothelial cells [5–10].
There are several assays to determine PAPP-A concentrations. It is necessary to choose 
an adequate method, since, in physiological conditions, the concentration of PAPP-A in 
adult males and non-pregnant females is very low. Moreover, in pregnant women the pro-
tein is present mainly as a heterotetramer (i.e. complexed with major basic protein), while 
in patients with acute coronary syndrome the non-complexed homodimer, or free PAPP-A, 
dominates [2, 3, 6, 9, 10]. 
A significantly increased serum PAPP-A concentrations were observed in patients with 
severe atherosclerosis, in the course of acute coronary syndromes connected with the plaque 
rupture, as well as in the course of kidney diseases [3, 9–11]. The increase of PAPP-A in 
end-stage renal disease patients treated with maintenance hemodialysis, and the prognostic 
value of PAPP-A for the assessment of long-term outcome in hemodialysis patients, were 
first reported in 2003. It was observed that the concentrations of PAPP-A in dialysis patients 
are, on average, three times higher than in healthy population (both the free and complexed 
forms of PAPP-A are increased); however, these values are nearly 100–1000 lower than the 
values registered in the first trimester of pregnancy [2–7]. Additionally, patients treated 
with hemodialysis tended to have higher PAPP-A than those undergoing peritoneal dialysis 
[3, 12]. Importantly, some authors observed the changes in PAPP-A concentrations during 
a single hemodialysis session. PAPP-A increased in the early phase of a hemodialysis session, 
and subsequently, it normalized by the end of the session. The initial increase in PAPPA-A 
was attributed to the possible influence of heparin [8, 13]. 
On contrary, in one of recent studies, Abdel-Messeih et al. [14] observed that a significant 
increase in the concentration of PAPP-A occurs proportionally to the duration of dialysis, 
and consequently, referred to PAPP-A as a new acute-phase protein. The increase in PAPP-A 
during a dialysis session may result from the production of PAPP-A due to the contact with 
synthetic dialysis membranes, or due to the release of PAPP-A from vascular endothelial 
cells [14]. A contact of blood with dialysis membranes leads to the activation of circulat-
ing neutrophils and monocytes. This, in turn, stimulates the production of reactive oxygen 
species and cytokines, and leads to chronic inflammation [15]. Moreover, numerous inter-
esting correlations between PAPP-A and placental growth factor, matrix metalloproteinases 
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MMP-2 and MMP-9, cardiac markers, such as troponin (cTnI) or brain natriuretic protein 
(BNP), as well as serum creatinine were observed in dialysis patients [2, 7, 16]. In patients 
with chronic kidney disease (CKD), the concentration of PAPP-A is significantly reduced 
after kidney transplantation, and it correlates with the function of the transplanted organ [4]. 
The aim of this study was to evaluate the diagnostic usefulness of PAPP-A serum con-
centrations in CKD patients treated with maintenance hemodialysis and its relationships 
with the duration of dialysis treatment. In particular, the study investigated the associations 
between serum PAPP-A and the results of laboratory tests performed in order to monitor 
health status in hemodialysed patients, i.e. complete blood counts and the markers of iron 
metabolism, N-terminal pro-brain natriuretic peptide (NT-proBNP), the markers of electro-
lyte and mineral homeostasis, as well as the markers of inflammation and nutritional status. 
Materials and methods
The study included 78 consecutive patients with CKD stage G5, receiving maintenance he-
modialysis treatment at the Department of Nephrology, Jagiellonian University Medical Col-
lege in Cracow, Poland. The patients’ mean age was 57.1 ± 14.3 years (range: 20 to 83 years) 
and median duration of hemodialysis treatment was 60 months (range: 12–360 months). All 
patients received 4-hour dialysis sessions 3 times a week, using polysulphone dialyzers and 
low molecular weight heparin anticoagulation. Only patients with stable disease course for at 
least 3 months were included. Patients with diabetes, any acute conditions, or neoplasm were 
excluded. The study protocol was approved by the Bioethical Committee of the Jagiellonian 
University in Cracow, Poland. Each patient has given the written informed consent for the study.
Blood samples for laboratory tests were drawn from the arteriovenous fistula or from 
the dialysis catheter before initiation of the dialysis session and, importantly, before admin-
istration of heparin. K2-EDTA anticoagulated whole blood samples were used for complete 
blood counts. Serum samples were used for biochemical and immunochemical tests.
The complete blood counts were performed using the 5-diff Sysmex XE 2100 automatic 
hematology analyzer. The routine biochemical and immunochemical tests, i.e. albumin, urea, 
intact parathormone (iPTH), iron, unsaturated iron binding capacity (UIBC) and total iron 
binding capacity (TIBC), enzymes (alanine and aspartate aminotrasferase, alkaline phospha-
tase), sodium, potassium, total calcium, and phosphate were carried out using the Cobas 
6000 automatic analyzer (Roche Diagnostica, Mannheim, Germany). PAPP-A concentra-
tions were measured by electrochemiluminescence immunoassay (ECLIA) with Cobas e601 
analyzer (Roche Diagnostica, Mannheim, Germany). Serum prealbumin (PRE), C-reactive 
protein (CRP), alpha-1-acid glycoprotein (AAG) were measured using BN II Nephelometer 
(Siemens Healthcare Diagnostics, Germany).
In addition, the following indices of nutritional status were calculated: Cancer Serum 
Index (CSI), CRP/PRE, Prognostic Inflammatory and Nutrition Index (PINI) and Glasgow 
Prognostic Score (GPS), using the following formulas: CSI = AAG [g/L] / PRE [g/L] [17]; 
GPS = 0 was assumed for CRP <10 mg/L and albumin >35 g/L; GPS = 1 for CRP >10 mg/L 
and albumin >35 g/L; and GPS = 2 for CRP >10 mg/L and albumin <35 g/L [18]; PINI = 
(CRP × AAG) / (albumin × PRE) [19]. 
Serum pregnancy-associated plasma protein. A correlates with inflammation and malnutrition... 
40
Statistical analysis
Qualitative data are presented as a number of patients in a given category and the percent-
age of the appropriate group. Qualitative data are shown as mean ± standard deviation or 
median (25–75 percentile), depending on distribution as tested with Shapiro-Wilk’s test. The 
differences between groups were tested using t-test or the Mann-Whitney test. The correla-
tions were assessed using Pearson’s coefficient, after the logarithmic transformation (natural 
logarithm — ln) of right-skewed variables. The multiple linear regression was adjusted for 
age and sex. The results were considered statistically significant at p<0.05. Calculations were 
performed using Statistica 10.0 (StatSoft) software.
Results
The median PAPP-A concentrations in hemodialyzed patients were almost two times higher than 
the upper reference limit (Table 1), however, the maximum values in the studied group reached 
14-times the upper reference limit, i.e. 140 mIU/L. The studied group was divided according 
to the duration of dialysis treatment, the median duration of hemodialysis was 60 months. 
There were no statistically significant differences regarding the clinical data and the results 
of laboratory tests between the patients dialyzed for shorter and for longer periods (Table 1). 
Associations between serum PAPP-A and blood counts and iron homeostasis
 
In studied patients, the average concentrations of hemoglobin (Hgb), the value of hematocrit 
(Hct) and the number of red blood cells (RBC) were low comparing to the reference ranges, 
although the average Hgb concentrations fell within the target range, as proposed by KDIGO 
(Table 1). RBC, Hct and Hgb values were lower than corresponding reference values in, re-
spectively, 92%, 84% and 94% of men, and 56%, 96% and 70% of women. The mean RDW-CV 
value was higher than the upper reference limit, reflecting mild anisocytosis in most patients. 
Median iron concentrations and UIBC values were within the respective reference rang-
es, while TIBC values were around the lower reference limit, irrespective of the duration of 
dialysis therapy (Table 1). 
No correlations were observed between serum PAPP-A concentrations and the parameters 
of complete blood counts. Also, there were no statistically significant correlations between ln 
(PAPP-A) and the markers of iron metabolism, although some tendency toward negative correla-
tions with TIBC and UIBC was observed, especially among longer dialyzed patients (Table 2). 
Association between serum PAPP-A and NT-proBNP
The median concentrations of NT-proBNP in hemodialyzed patients were 30–40-times higher 
comparing with reference limit (Table 1). Significant positive correlation was observed be-
tween ln (PAPP-A) and ln (NT-proBNP) in the whole group of patients and in the subgroup 
dialyzed for ≤ 60 months (Table 2). In multiple regression, this association was independent 
of age and sex of patients (beta = 0.32 ± 0.14; p = 0.034).
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Table 1. Clinical and selected laboratory data in hemodialyzed CKD patients.
Variables Patients dialyzed for  ≤60 months (N = 39)
Patients dialyzed for  
>60 months (N = 39) p-values
Reference intervals/ 
target values
Male gender [N/(%)] 26 (67) 25 (64) 0.9 –
Age [years] 58 ± 11 57 ± 15 0.9 –
Hemodialysis vintage 
[months] 36 (24–48) 168 (84–210) <0.001 –
BMI [kg/m2] 25.7 ± 3.7 23.9 ± 4.3 0.1 18.5–24.9
WBC [103/μL] 6.73 ± 2.22 6.67 ± 1.53 0.9 4.0–10.0
RBC [106/μL] 3.58 ± 0.45 3.59 ± 0.58 0.9 F: 3.5–5.0/M: 4.5–6.5
Hemoglobin [g/L] 10.7 ± 1.6 10.6 ± 1.4 0.9
F: 11.0–15.0/ 
M: 12.0–17.0 /
9.0–11.5 [23]*
Hematocrit [%] 33.0 ± 4.8 33.0 ± 4.4 0.7 F: 37.0–47.0/ M: 40.0–54.0
MCV [fL] 92.3 ± 5.4 92.5 ± 4.8 0.6 82.0–92.0
MCH [pg] 29.8 ± 2.0 29.6 ± 1.6 0.7 27.0–31.0
MCHC [g/L] 32.3 ± 0.9 32.0 ± 0.8 0.1 32.0–36.0
RDW-CV [%] 14.7 ± 1.6 14.6 ± 1.3 0.7 12.1–14.1
PLT [103/μL] 191 (164–244) 238 (182–280) 0.1 150–350
Urea [mmol/L] 23.74 ± 5.17 22.5.40 0.3 2.76–8.07
Iron [µmol/L] 13.2 (10.7–14.9) 11.0 (9.65–13.7) 0.1 5.83–34.50
UIBC [µmol/L] 31.2 (25.1–34.6) 28.2 (23.7–34.8) 0.6 F: 24.2–70.1/ M: 22.3–61.7
TIBC [µmol/L] 41.8 (37.8–49.2) 38.7 (34.9–47.4) 0.2 40.80–76.60
Transferrin saturation 
[%] 29.9 (24.4–35.5) 27.7 (23.1–32.9) 0.1 <30 [23]*
iPTH [ng/mL] 401 (144–664) 301 (132–488) 0.4 15.0–65.0/130–585 [26]**
Calcium [mmol/L] 2.08 ± 0.20 2.10 ± 0.21 0.8 2.15–2.55
Phosphate [mmol/L] 1.94 ± 0.62 1.97 ± 0.57 0.8 0.81–1.45
Potassium [mmol/L] 5.31 ± 0.72 5.52 ± 0.57 0.1 3.50–5.10
Sodium [mmol/L] 139.3 ± 2.9 139.3 ± 2.2 0.9 136.0–145.0
Albumin [g/L] 32.1 ± 7.1 34.5 ± 6.4 0.1 35.0–50.0
Prealbumin [g/L] 0.37 ± 0.11 0.38 ± 0.11 0.5 0.2–0.4
CRP [mg/L] 3.72 (1.5–8.76) 5.32 (3.24–15.1) 0.1 0.16–5.00
AAG [g/L] 1.27 ± 0.25 1.23 ± 0.31 0.5 0.5–1.2
PINI 0.38 (0.15–1.23) 0.45 (0.22–1.83) 0.4 <1
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Variables Patients dialyzed for  ≤60 months (N = 39)
Patients dialyzed for  
>60 months (N = 39) p-values
Reference intervals/ 
target values
CSI 3.27 (2.72–4.76) 3.10 (2.67–3.80) 0.3 –
GPS: 0/1/2 [N/(%)] 29 (74)/9 (23)/1 (3) 22 (56)/10 (26)/7 (18) 0.1 0
CRP/PRE 0.009 (0.003–0.030) 0.013 (0.008–0.043) 0.1 –
NT-proBNP  
[pg/mL] 3851 (731–23037) 5119 (2049–9563) 0.6 <125
PAPP-A [mIU/L] 18.0 (14.0–23.0) 18.0 (15.0–22.0) 0.7 4.0–10.0
**The range of expected values by KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease [23]; 
**KDIGO Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Dise-
ase — Mineral and Bone Disorder (CKD-MBD) [26]; WBC — white blood cells; RBC — red blood cells; MCV — mean 
corpuscular volume; MCH — mean corpuscular hemoglobin; MCHC — mean corpuscular hemoglobin concentration; 
RDW — red distribution width; PLT — platelets; TIBC — total iron-binding capacity; UIBC — unsaturated iron-binding 
capacity; CRP — C-reactive protein; AAG — acid alpha 1 glicoprotein; PINI — Prognostic Inflammatory and Nutritional 
Index; GPS — Glasgow Prognostic Score; PRE — prealbumin; CSI — Cancer Serum Index; NT-proBNP — N-terminal 
pro-brain natriuretic peptide; PAPP-A — pregnancy-associated plasma protein A
Table 2. Correlations between ln (PAPP-A) and selected variables in hemodialyzed CKD patients.
Variables
Total cohort (N = 78) Patients dialyzed for  ≤60 months (N = 39)
Patients dialyzed for  
>60 months (N = 39)
R p-values R p-values R p-values
Sodium 0.28* 0.020 0.31 0.065    0.50* 0.002
Potassium 0.17 0.2 0.23 0.2 –0.09 0.5
Calcium 0.01 0.9 –0.06 0.7 –0.12 0.4
Phosphate 0.10 0.4 0.13 0.4 –0.14 0.4
ln (PTH) 0.06 0.6 0.01 0.9 0.06 0.7
ln (iron) –0.01 0.9 –0.01 0.9 0.16 0.3
UIBC –0.21 0.076 –0.22 0.2 –0.32 0.056
TIBC –0.22 0.054 –0.22 0.2 –0.29 0.085
ln (transferrin 
saturation) 0.12 0.3 0.12 0.5 0.30 0.1
ln (CRP) 0.18 0.1     0.40* 0.023 –0.09 0.6
GPS 0.13 0.3 0.38* 0.030 –0.26 0.1
ln (CRP/PRE) 0.19 0.1 0.42* 0.021 –0.12 0.5
ln (CSI) 0.10 0.4 0.29 0.086 –0.21 0.2
ln (PINI) 0.15 0.2 0.36* 0.046 –0.13 0.4
ln (NT-proBNP) 0.24* 0.045 0.37* 0.026 0.11 0.5
*Statistically significant correlations; PTH — parathormon; UIBC — unsaturated iron-binding capacity; TIBC — total iron-
binding capacity; CRP — C-reactive protein; GPS — Glasgow Prognostic Score; PRE — prealbumin; CSI — Cancer Serum 
Index; PINI — Prognostic Inflammatory and Nutritional Index; NT-proBNP — N-terminal pro-brain natriuretic peptide
Małgorzata Mazur-Laskowska, Agnieszka Gala-Błądzińska et al.
43
 Associations between serum PAPP-A and the markers of electrolyte  
and mineral homeostasis 
In studied patients, serum concentrations of potassium were high, while sodium fell within 
the reference ranges (Table 1). Serum sodium positively correlated with ln (PAPP-A) in the 
whole group of patients, and in particular among those with long dialysis therapy duration 
(Table 2). Also, serum potassium positively correlated with PAPP-A among studied men 
(R = 0.52; p <0.001; Fig. 1a).
Also, serum concentrations of phosphate and iPTH were high, whereas calcium concentra-
tions were low in most patients as compared to the reference intervals. The majority of patients 
had iPTH concentrations within the target values recommended by KDIGO. No significant 
correlations were observed between calcium, phosphate and iPTH and serum PAPP-A concen-
trations, irrespective of dialysis therapy duration (Table 2). However, there was positive correla-
tion between ln (PAPP-A) and phosphate among studied man (R = 0.34; p = 0.026; Fig. 1b).
Fig. 1. The associations between serum PAPP-A concentrations and serum potassium (a) and phosphate (b) 
in men treated with maintenance hemodialysis.
Associations between serum PAPP-A and the markers of inflammation  
and nutritional status
The average BMI values fell within the normal range (Table 1). We observed low albumin 
concentrations in studied patients (Table 1); 54% of them had albumin concentrations be-
low 35 g/L. In 19% of patients, albumin concentration fell within the range of 25–29 g/L, 
and in 14% of patients it was ≤24 g/L (i.e. the values associated with severe malnutrition). 
Additionally, 7.6% of patients had low PRE concentrations. CRP concentrations were high, 
especially in patients with longer dialysis therapy duration (Table 1). Also, most patients 
have AAG concentrations exceeding upper reference limit (Table 1).
The values of nutritional indices are shown in Table 1. PINI>1 was noted in 31% of 
patients, 35% had higher GPS values (1 or 2). The maximum values of nutritional param-
eters were as follows: CSI 9.09; PINI 14.10; and CRP/PRE 0.255. The CSI and PINI values 
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were significantly higher in women than in men (median 3.6 vs 2.9; p <0.001 and 0.9 vs 0.3; 
p <0.003, respectively). 
In patients undergoing hemodialysis treatment for ≤60 months, ln (PAPP-A) significantly, 
positively correlated with ln (CRP), GPS, ln (CRP/PRE) and ln (PINI) (Table 2). 
Discussion
Despite the significant advancements in dialysis treatment, it is still associated with high 
mortality, and hence, it is far from being ideal. It is estimated that mortality is nearly 9 times 
higher among CKD patients undergoing maintenance dialysis than among general popula-
tion. About one half of deaths among dialysed patients are caused by cardiovascular causes 
[6, 8, 20]. Frequently, sudden deaths are caused by the ventricular arrhythmias associated 
with hemodialysis procedure, i.e. sudden changes in potassium concentrations or volemia 
[21]. However, many chronic factors such as: anemia, mineral and bone disorders, or the 
malnutrition-inflammation-atherosclerosis (MIA) syndrome contribute to cardiovascular 
morbidity and mortality [3, 22]. 
In patients with cardiovascular events and the recognized renal failure, high PAPP-A 
concentrations were observed [14]. Also, Coskun A et al. [12] observed significantly high-
er PAPP-A concentrations among hemodialyzed patients than among healthy controls 
[12]. The latter study made an attempt to find correlations between PAPP-A concentra-
tion and the main factors influencing morbidity and mortality in hemodialyzed patients. 
Taking into account the differences in methods used to measure PAPP-A concentrations, 
the levels of PAPP-A observed in the mentioned studies were comparable to what was 
observed in our patients (average values about 1.5–2.5 times higher than control val-
ues). The increase in PAPP-A concentration has been considered an indicator of a signif-
icant damage to endothelial cells, and of an increased risk of death in dialyzed patients 
[2, 5].
Patients enrolled in our study were mostly adult men with normal weight or overweight. 
We observed normocytic anemia with high anisocytosis values (yet with Hgb concentrations 
within the recommended target range for dialysis patients); secondary hyperparathyroidism 
with accompanying hyperphosphatemia and hypocalcemia (typical for hemodialysis pa-
tients); hyperkalemia; increased CRP (mainly in those dialyzed for longer periods) and low 
concentrations of serum albumin. We observed no differences in laboratory data between 
patients hemodialyzed for shorter and longer periods, however, different correlations of 
PAPP-A were shown in those two groups of patients.
In patients dialyzed longer than 60 months, a positive association was observed be-
tween serum PAPP-A and serum sodium. To our knowledge, such association has not been 
previously reported. KDIGO [23] recommends that the intake of sodium chloride in CKD 
patients should not exceed 5 g per day. High sodium intake, particularly by patients without 
residual diuresis, is a risk factor for high blood pressure and it contributes to excess water 
accumulation between dialysis sessions. Hypervolemia is, in turn, one of the major causes 
of heart failure in hemodialyzed patients. Interestingly, we also observed positive association 
between PAPP-A and potassium concentrations in men.
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On the other hand, in the group of patients with shorter dialysis treatment, PAPP-A 
positively correlated with NT-proBNP — the serum biomarker of heart failure. Natriuretic 
peptides (e.g. BNP), which control the water and sodium balance and maintain the car-
diovascular homeostasis, are released by cardiomyocytes stretched due to the increase in 
the preload or afterload (e.g. in the case of excess water accumulation) [24, 25]. Kalusova 
et al. [5], observed that in a group of 261 patients receiving maintenance dialysis, the con-
centrations of natriuretic peptides were significantly higher than among healthy controls. 
Additionally, these authors observed a correlation between PAPP-A and the total mortality 
caused mainly by cardiovascular events [5]. 
Another finding of our study is the positive association between serum PAPP-A and 
CRP, as well as the indices of poor nutritional status, i.e. GPS, CRP/PRE and PINI, in pa-
tients dialyzed for ≤ 60 months. This observation should encourage clinicians to look for the 
causes of malnutrition and inflammatory states in dialysis patients. Malnutrition may result 
from clinically significant loss of proteins in the course of nephrotic syndrome in patients 
with preserved residual diuresis, or from lack of appetite in uremic patients. However, the 
increase in the values of inflammatory markers and indices of malnutrition/inflammation 
may in many cases be due to late initiation of hemodialysis (because of poor availability of 
specialist care by nephrologist, or delayed consent of the patient to dialysis treatment, or 
delayed diagnosis of CKD). In addition, the restrictions in protein intake in advanced CKD 
(less than 0.8 g/kg body weight/day according to KDIGO), meant to prevent hyperphospha-
temia and secondary hyperparathyroidism, may also account for malnutrition [26].
The positive correlation between PAPP-A and CRP in our study agrees with the ob-
servation by Kalousova et al. [5], according to whom, in dialysis patients, PAPP-A is not 
only an independent biomarker of total mortality, but also of mortality caused by infections 
[2, 5, 7]. CRP is a recognized marker of inflammatory states; it changes dynamically de-
pending on the patient’s clinical condition. Hemodialysis patients are especially vulnerable 
to infections. Additionally, the chronic inflammatory state is one of the factors that consti-
tute the MIA syndrome. 
Finally, we did not observe the correlation between PAPP-A and iPTH, as reported by 
Coskun et al. [12]. However, PAPP-A positively correlated with serum phosphate in men. 
The differences in patients’ characteristic and the different method of PAPP-A measurement 
may be in part responsible for the discrepancy.
Although limited by the low number of patients, our study point towards the usefulness 
of PAPP-A as a marker associated with cardiovascular dysfunction, inflammatory states and 
malnutrition in hemodialyzed patients. 
Conclusions
In hemodialysis patients the average serum PAPP-A concentrations were significantly in-
creased. In patients with shorter dialysis vintage, PAPP-A correlated with NT-proBNP, as well 
as with the markers of inflammatory state and malnutrition. On the other hand, in patients 
with longer duration of hemodialysis therapy, PAPP-A positively correlated with serum 
sodium. Taking into account the published associations between PAPP-A and mortality, it 
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seems reasonable to restrict the intake of fluids and salt in dialyzed patients. Additionally, 
the restrictions in protein should take into account the patient’s nutritional status. Summa-
rizing, serum PAPP-A seems a useful biomarker associated with cardiovascular dysfunction, 
inflammatory states and malnutrition in hemodialysis patients. 
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